Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZW418
- Development stage
- Unknown
- Lead developer
- Zymeworks
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ZW418 is a bispecific T-cell engager (BiTE) designed to target B7-H3 (CD276) and CD3. Developed by Zymeworks using their proprietary Azymetric™ and EFECT™ platforms, the molecule is engineered to redirect T-cell cytotoxicity against B7-H3-expressing tumor cells. B7-H3 is an immune checkpoint protein frequently overexpressed in a wide range of solid tumors, including lung, prostate, and breast cancers, and is associated with poor prognosis and immune evasion. ZW418 incorporates specific Fc modifications to reduce the risk of systemic cytokine release syndrome (CRS) while maintaining potent anti-tumor efficacy. It is currently being investigated for the treatment of advanced B7-H3-positive solid tumors.
- Other names
- B7-H3 x CD3 bispecific antibodyB-7-H3 x CD3 bispecific antibodyB 7-H3 x CD3 bispecific antibody
02
Targets
PTK7 (Protein tyrosine kinase 7)HRAS (H-Ras protein)
Beyond the preview
Go deeper on ZW418.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZW418.